Inserm Transfert

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability. They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways. Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

BIOMODEX is an innovative medical technology company based in Paris and Boston using 3D printing to create tissue-like anatomical twins from medical images, for patient-specific rehearsal and advanced training. The anatomically accurate twin is designed to provide critical tactile feedback to users which, when paired with our simulated blood flow stations, offers a unique and tailored end to end physician experience.

ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public). The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and the BSL4 laboratory Inserm-Jean Mérieux. ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules. The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

BIOMODEX is an innovative medical technology company based in Paris and Boston using 3D printing to create tissue-like anatomical twins from medical images, for patient-specific rehearsal and advanced training. The anatomically accurate twin is designed to provide critical tactile feedback to users which, when paired with our simulated blood flow stations, offers a unique and tailored end to end physician experience.

Inception IBD is focused on translating academic discoveries in the field of IBD

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability. They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.

Sensorion, a Clapiers, France-based biopharmaceutical company specifically dedicated to the development of innovative and targeted therapeutic solutions to treat vestibular deficits.

AAVLife's lead indication is for Friedreich’s Ataxia Cardiomyopathy. Their program is based on the successful use of a gene-therapy approach in a mouse model developed to mimic the gene defect and cardiac symptoms of Friedreich’s Ataxia. The approach made use of an adeno-associated virus (AAV) to introduce a normal gene into cardiac tissue. The therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure. AAVLife has progressed research of this gene-therapy approach to inform decisions about dosing and route of administration to be used in a clinical trial. The company will be conferring with regulatory authorities about toxicity-study requirements and clinical-trial design. The goal is to commence a clinical trial in 2015 to evaluate gene therapy for heart disease associated with Friedreich’s Ataxia. An observational study will be initiated in 2014 as a run-up to treating patients in a Phase I/II study. Friedreich’s Ataxia is a life-threatening disorder caused by a genetic mutation that results in progressive neurologic and cardiac symptoms typically first appearing in childhood or during the teenage years. Cardiac disease accounts for the majority of deaths due to Friedreich’s Ataxia, with death usually occuring in early adulthood. They are passionate in their quest to serve patients and value their relationship with patient communities and the organizations that serve them.

Bioaxial develops new technology for super-resolved fluorescence microscopy for extended imaging of live cells with a resolution of less than 100 nanometers. The optical modules manufactured by Bioaxial adapt as an add-on for commercial microscopes. Bioaxial has filed four patents and has acquired a fifth, all of which are held exclusively by the company.

Hemarina SA. is a privately held biotechnology company focused on the research, and development of oxygen-carriers for medical applications. Dr. Franck Zal, an expert in the field of invertebrate hemoglobin and oxygen transport, founded Hemarina after having spent more than fourteen years in academic research centers (CNRS, University of California at Santa Barbara USA and University of Antwerpen, Belgium) studying the relationships between the structure and function of invertebrate respiratory pigment (annelid’s extracellular hemoglobin and crustacean hemocyanin). The discoveries arising from his research on extracellular hemoglobin coming from marine invertebrates and their effective oxygen transport system have been patented and published in numerous scientific journals and form the basis of Hemarina’s technologies. Hemarina’s approach to the development of oxygen transport agents is based on the observation of marine worms colonizing extreme environments and the study of their respiratory adaptations. Hemarina’s lead product, HbAm, is designed to deliver oxygen effectively and efficiently to tissues at risk of oxygen deprivation. Hemarina has already a passed panel of strong proof of concepts obtained during preclinical trials.

Hemarina SA. is a privately held biotechnology company focused on the research, and development of oxygen-carriers for medical applications. Dr. Franck Zal, an expert in the field of invertebrate hemoglobin and oxygen transport, founded Hemarina after having spent more than fourteen years in academic research centers (CNRS, University of California at Santa Barbara USA and University of Antwerpen, Belgium) studying the relationships between the structure and function of invertebrate respiratory pigment (annelid’s extracellular hemoglobin and crustacean hemocyanin). The discoveries arising from his research on extracellular hemoglobin coming from marine invertebrates and their effective oxygen transport system have been patented and published in numerous scientific journals and form the basis of Hemarina’s technologies. Hemarina’s approach to the development of oxygen transport agents is based on the observation of marine worms colonizing extreme environments and the study of their respiratory adaptations. Hemarina’s lead product, HbAm, is designed to deliver oxygen effectively and efficiently to tissues at risk of oxygen deprivation. Hemarina has already a passed panel of strong proof of concepts obtained during preclinical trials.

CellVir, founded in March 2006, is developing a new generation of anti-retrovirals based on a novel therapeutic mode of action. Instead of targeting the inhibition of the catalytic activity of viral enzymes (as do most of today's drugs), CellVir's approach targets host-virus protein-protein interactions which have been shown to be essential for viral replication in infected cells. Drugs operating via this novel mode of action offer two key potential advantages: complementarity to existing drugs because of their lack of susceptibility to cross resistance mechanisms, and a reduced occurrence of viral mutations that lead to drug resistance.

ScreenCell is a provider of rare cell isolation solutions for medical and research applications. Circulating Tumor Cells - Available in minutes Characterization of CTC’s by cytology, molecular, culture or sequencing methods requires initial separation from peripheral blood – without contamination. ScreenCell® size exclusion technology delivers the fastest, easiest and most reproducible start to your research

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.